18 Apr 2023 OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
18 Apr 2023 Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
18 Apr 2023 Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023
17 Apr 2023 aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
17 Apr 2023 Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
17 Apr 2023 Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
17 Apr 2023 ZielBio to Present New Research on the Utility of Cancer-Specific Plectin (CSP) and ZB131 in Antibody-Drug Conjugates at AACR Annual Meeting 2023
17 Apr 2023 Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023
17 Apr 2023 Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
17 Apr 2023 Lassen Therapeutics Presents Data Demonstrating Anti-IL18 Binding Protein Antibody Efficacy and Enhancement of Anti-Tumor Immunity at AACR Annual Meeting
17 Apr 2023 AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
17 Apr 2023 23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
17 Apr 2023 Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
17 Apr 2023 Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
17 Apr 2023 Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
17 Apr 2023 Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
17 Apr 2023 Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
17 Apr 2023 Faron Pharmaceuticals Announces BEXMAB Study Update
15 Apr 2023 Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
14 Apr 2023 Alvotech Provides Regulatory Update on AVT02 Biologics License Application
14 Apr 2023 Harbour BioMed Announces Results of Phase Ib Clinical Trial of Porustobart in Combination with Toripalimab in Advanced High-Grade Neuroendocrine Neoplasms at AACR Annual Meeting
14 Apr 2023 TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics
14 Apr 2023 Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare
14 Apr 2023 U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab
13 Apr 2023 FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up